Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study

Abstract

Glucocorticoid administration is a common clinical practice that attempts to decrease the inflammation associated with and improve the resectability of canine mast cell tumors (MCTs). However, the impact of neoadjuvant glucocorticoids on the histological features and proliferation indices of canine MCTs is unknown. The objective of this study was to evaluate changes in tumor grade, mitotic count, Ki67, AgNOR, and AgNORxKi67 scores following short-course anti-inflammatory neoadjuvant prednisone in canine patients with MCTs. This was a prospective single-arm pilot study. Client-owned dogs with treatment-naïve cytologically confirmed MCTs were enrolled. Patients underwent an initial incisional biopsy followed by a 10–14-day course of anti-inflammatory prednisone and surgical resection. All histological samples were randomized, masked, and evaluated by a single pathologist. Unstained paired pre- and post-treatment samples were submitted to a commercial laboratory for Ki67 and AgNOR immunohistochemical analysis. There were 11 dogs enrolled with 11 tumors. There were no statistical differences between the pre- and post-treatment histological parameters of mitotic index, Ki67, AgNOR, or Ki67xAgNOR. There were no clinically significant alterations between pre-treatment and post-treatment in the assignment of tumor grades. A short course of anti-inflammatory prednisone does not appear to alter the histological parameters that affect grade determination or significantly alter the proliferation indices in canine MCTs.

Pre‐operative neoadjuvant vinblastine‐prednisolone in canine mast cell tumours: A single‐centre retrospective cohort study

“…Additionally, the effect of neoadjuvant VBL‐P on MC and proliferation indices remains unclear. Whereas previous evidence in dogs suggest that neoadjuvant prednisolone does not affect most histological features, 21,41,59 several studies in humans highlight the effect of cytotoxic chemotherapy on MC and proliferation indices. Whereas in vitro studies suggest that microtubules‐disruptive agents such as vinblastine and taxol can artificially increase the MC via cell cycle arrest, 60,61 clinical studies showed that taxanes‐based‐NAC protocols can decrease MC 61–64 .…”

Mastocitoma cutáneo de alto grado diseminado en un canino: Reporte de caso

“…2.1. pp. 6 -21. mayo -junio 2023 www.alfapublicaciones.com fármacos en la clínica está destinado a disminuir la inflamación y mejorar la resecabilidad del MCT (Klahn et al, 2022).…”